Company news

Axogen, Inc. news in 2025

Axogen, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

December 16, 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

December 2, 2025

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

November 3, 2025

Axogen, Inc. Reports Third Quarter 2025 Financial Results

October 28, 2025

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

October 14, 2025

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

August 24, 2025

Axogen, Inc. Reports Second Quarter 2025 Financial Results

August 5, 2025

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

July 28, 2025

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

July 21, 2025

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 27, 2025

Axogen, Inc. Reports 2025 First Quarter Financial Results

May 7, 2025

Axogen Announces Chief Financial Officer Transition

May 7, 2025

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

April 23, 2025

Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 23, 2025

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

February 24, 2025

Axogen, Inc. To Host Analyst & Investor Day on March 4th

February 24, 2025

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

February 10, 2025

Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2025

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

January 9, 2025

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2025

Calls in 2025

Decks in 2025